In today’s recent session, 0.59 million shares of the Checkpoint Therapeutics Inc (NASDAQ:CKPT) have been traded, and its beta is 1.34. Most recently the company’s share price was $3.35, and it changed around -$0.14 or -4.29% from the last close, which brings the market valuation of the company to $162.18M. CKPT at last check was trading at a discount to its 52-week high of $4.50, offering almost -34.33% off that amount. The share price’s 52-week low was $1.38, which indicates that the recent value has risen by an impressive 58.81% since then. We note from Checkpoint Therapeutics Inc’s average daily trading volume that its 10-day average is 3.77 million shares, with the 3-month average coming to 1.36 million.
Checkpoint Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CKPT as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Checkpoint Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Instantly CKPT has been showing red trend so far today with a performance of -4.29% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.70 on recent trading dayincreased the stock’s daily price by 9.46%. The company’s shares are currently up 46.07% year-to-date, but still down -10.80% over the last five days. On the other hand, Checkpoint Therapeutics Inc (NASDAQ:CKPT) is -21.85% down in the 30-day period. We can see from the shorts that 5.56 million shares have been sold at a short interest cover period of 5.7 day(s).
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Checkpoint Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 63.17 percent over the past six months and at a 71.29% annual growth rate that is well above the industry average of 16.70%. The year-over-year growth rate is expected to be -76.70%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 10.33k in revenue for the current quarter. 1 analysts expect Checkpoint Therapeutics Inc to make 4.53M in revenue for the current ending quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 72.17%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 26.32%.
CKPT Dividends
Checkpoint Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.52% of Checkpoint Therapeutics Inc shares, and 13.91% of them are in the hands of institutional investors. The stock currently has a share float of 16.47%.
